Abstract. The expression of genes required for progression through the cell cycle is highly modulated through a regulatory axis containing the E2F transcription factor and retinoblastoma tumour suppressor protein families. One of the genes regulated through this mechanism encodes the B-Myb transcription factor, which has been shown to be critically required for early embryonal development in the mouse. Transcriptional activity of B-
Introduction
The vertebrate Myb transcription factors comprise a small family of important regulatory proteins. The prototypical member, c-Myb, is the cellular progenitor of the oncogene carried by the AMV and E26 chicken retroviruses that transform haematopoietic cells in vivo and in vitro (reviewed in [1] ). Two other members of this family, A-Myb and B-Myb, were subsequently discovered using a c-Myb probe to screen human cDNA libraries [2] . These three Myb proteins share a similar domain organisation (see fig. 1 for B-Myb domains). The most conserved region is the DNA-binding domain located in the N terminus, which is composed of three imperfect repeats of 51 -52 amino acids that recognise the canonical Mybbinding site (MBS) C/TAACNG [3, 4] . The central portions of these proteins comprise a less highly conserved acidic domain which is involved in transcription activa-* Corresponding author. † Current address: Friedrich Miescher Institute, Maulbeerstrasse 66, 4058 Basel (Switzerland), e-mail: mjoaquin@fmi.ch tion and a conserved region (CR) which has variously been associated with positive and negative effects on transcriptional activity [5 -9] . The C terminus comprises an autoregulatory domain (negative regulatory domain: NRD) that suppresses transactivation function [6, 8, 10 -14] . The fact that three different Myb proteins have been found in higher vertebrates suggests that they have specific and distinct functions. c-Myb is expressed at high levels in most haematopoietic precursor cells and plays a crucial role in blood cell development [1, 15, 16] . Indeed, mice lacking a functional c-myb gene die at day 15 of gestation with multiple defects in fetal liver haematopoiesis [17] . A-myb is widely expressed in mitotically active cells during embryogenesis and in the developing central nervous system, sperm cell precursors, female breast ductal epithelium and B lymphocytes [18] . Consistent with this expression pattern, male mice lacking A-Myb are infertile because of a block in spermatogenesis, and A-myb null females have underdeveloped breast tissue after pregnancy [19] . In marked contrast to the restricted expression patterns of c-myb and A-myb, B-myb is widely expressed in cycling cells of all lineages [2, 16, 20 -22] . B-myb is expressed early during mouse embryogenesis, before either c-myb or A-myb, and its expression is restricted to zones of cell proliferation [23] . Consistent with this, B-myb knock-out mice die at a very early stage of development (E4.5 -E6.5), and a requirement for BMyb in inner cell mass formation is indicated by the severely impaired proliferation of these pluripotent cells when blastocysts were explanted and cultured in vitro [24] . The fact that B-myb expression is strongly associated with proliferating cells of all lineages suggests that this gene may play an important and general role during the cell cycle. This notion is supported by studies showing that B-myb antisense oligonucleotides inhibit proliferation of myeloid, lymphoid, glioblastoma, fibroblast and neuroblastoma cell lines [25 -28] , while constitutive Bmyb expression allows BALB/c 3T3 fibroblasts to grow in low serum conditions [26] and prevents cell cycle arrest in interleukin (IL)-6-induced differentiation of M1 myeloid leukaemia cells [29] . The purpose of this review is to discuss recent developments in our knowledge of Bmyb regulation during the cell cycle and to suggest what part B-Myb may have in regulating cell proliferation.
Cell cyle regulation of B-myb transcription
The fact that B-myb transcription is very tightly regulated during the cell cycle provides a key piece of evidence that the B-Myb protein provides a function required in proliferating cells. Thus, early studies showed that B-myb mRNA levels were undetectable by Northern blot in 2390 M. Joaquin and R. J. Watson Cell cycle regulation by B-Myb murine fibroblasts and human keratinocytes arrested by serum deprivation [20, 21, 30] , and in quiescent human T and B lymphoid cells [16] . After stimulation of these cells, B-myb expression was not induced until mid to late G1, and reached its maximum levels during S phase. Moreover, in G2/M synchronised NIH 3T3 fibroblasts, B-myb mRNA levels were found to decrease in G1 before again peaking at S phase, indicating that B-myb transcription is determined by the cell cycle phase rather than by the presence of mitogens [21] . Run-on transcription studies showed that B-myb mRNA induction in late G1 is due largely to an increase in gene transcription [21] , suggesting that B-myb may be an E2F transcription factor-regulated gene. Indeed, the promoters of both the mouse and human B-myb genes contain a perfectly conserved E2F-binding site ( fig. 2 ) which we showed is critical for cell cycle regulation of transcription [30, 31] . Mutation of the B-myb promoter E2F-binding site resulted in constitutively high levels of expression throughout the cell cycle, a finding which ran counter to the prevailing view of the time that E2F is an activator of transcription. Co-expression of the 12S adenovirus E1A or human papillomavirus type 16 E7 genes enhanced the activity of the wild-type B-myb reporter activity, but not that of a B-myb promoter carrying a mutated E2F site. Since E1A and E7 target the Rb family of pocket proteins and disrupt their binding to E2F, the B-myb promotor was postulated to be regulated by transcriptional repression involving E2F complexes bound to members of the Rb family [31, 32] . Activation of transcription in late G1 would then utilise constitutively bound transactivators, such as Sp1, which recognise sites upstream of the E2F site, and whose activity is presumably suppressed in Figure 1 . The B-Myb protein. Schematic representation of the B-Myb protein showing the described domains: the N-terminal DNA-binding domain is composed of three subdomains R1, R2 and R3. The overall amino acid identity of this region among Myb proteins is 75%. Also shown are the adjacent acidic region, the conserved region (CR, which has an amino acid identity of 45 % among Myb proteins) and the negative regulatory domain (NRD). The serine and threonine residues phosphorylated by the action of cyclin/cdk2 kinases are shown (amino acid residues shown relate to mouse B-Myb). The four conserved lysine residues which are putatively acetylated by CBP/p300 are also indicated.
G0/early G1 by E2F/pocket protein complexes. In this simple model, activation of transcription therefore reflects derepression of the promoter ( fig. 2 ). The precise mechanism operating on transcriptional regulation of B-myb has been the subject of several studies. Using E7 mutants that discriminate between pocket proteins, we deduced that transcriptional repression depended on p107/E2F rather than Rb/E2F complexes in NIH3T3 fibroblasts [32] . In other cell types, p130 was the predominant protein found in E2F complexes binding to the B-myb promoter during quiescence [30, 33] . Evidence supporting the notion that B-myb promoter repression requires either p107 or p130 has come from studies of embryonic fibroblasts derived from gene knock-out mice [34] . Significantly, B-myb expression was unaffected in mouse embryo fibroblasts (MEFs) derived from either p107 -/-or p130 -/-knock-out animals; however, in double-knock-out p107 -/-; p130 -/-MEFs, B-myb transcription was strongly derepressed during G0/early G1.
Other genes such as cdc2, E2F1 and cyclin A2 were also deregulated in these cells. In contrast, B-myb expression was unaffected in Rb -/-MEFs, although the cyclin E and p107 genes were strongly deregulated in these cells. This study indicates a functional redundancy between p107 and p130 in repression of B-myb transcription during G0/early G1 that cannot be compensated for by Rb. Consistent with this conclusion, transfection of p107 -/-; p130 -/-MEFs with either p107 or p130 repressed the B-myb promoter, whereas pRb had no significant effect [34, 35] . The major question that arises from these findings is how does the B-myb promoter discriminate between E2F complexes containing p107/p130 and Rb? Certainly, Rb/E2F complexes are able to bind to the B-myb promoter in in vitro electrophoretic mobility shift assays (EMSAs) and, notably, these complexes are very abundant in quiescent p107 -/-;p130 -/-MEFs [34, 35] . However, in vivo methylation footprinting showed that the B-myb E2F site was CMLS, Cell. Mol. Life Sci. Vol. 60, 2003 Review Article 2391 Figure 2 . B-Myb: a cell cycle-regulated gene. The B-myb gene is precisely regulated along the cell cycle. In quiescent and G0-arrested cells, the B-myb promoter is highly repressed by a protein complex bound to the E2F site and downstream repression site (DRS). Among the proteins identified to date which are involved in B-myb repression are E2F4 and its partner DP, the Rb proteins p107 and p130, the histone deacetylase HDAC1 and the repressor mSinB3. Although the relevance of the DRS site on B-myb gene regulation has been well established, the nature of the downstream regulatory factor (DRF) has yet to be characterized. In this phase of the cell cycle, histones are mainly deacetylated. During mid to late G1, the repressor complex is removed and substituted by other proteins, and E2F1/3-DP complexes are transiently detected at that stage. The presence of histone acetylases (HATs) has also been described and may be responsible for the histone acetylation detected in this phase. Since HATs do not directly bind to DNA, they may interact through E2F1/3 (as described for CBP) or through additional factors (X) yet to be characterised. At the S phase of the cell cycle, B-myb transcription is fully derepressed and the promoter reaches its highest activity. During that phase, the E2F and DRS sites are unoccupied and histone acetylation is at its maximum. Transcription may also be driven by the cooperative activity of SP1 and B-Myb itself. The involvement of unknown proteins bridging Sp1 and B-Myb is also possible.
unprotected in p107 -/-;p130 -/-MEFs, indicating the absence of interacting E2F complexes in these cells, whereas the site was protected in wild-type and Rb -/-MEFs. Similar footprinting studies showed that this site is occupied in vivo in G0/early G1 when the B-myb promoter is repressed, but unoccupied at late G1/S when Bmyb is expressed [36] . Notably, the latter study suggests that activating E2F species (i. e. E2F-1, E2F-2 and E2F-3 unbound to pocket proteins), which are prevalent at late G1/S, do not bind stably to the B-myb promoter. This conclusion is consistent with the notion that B-myb transcription is regulated predominantly by a repressionderepression mechanism [31] . Overall, these findings suggest that discrimination between E2F complexes binding to the B-myb promoter depends upon chromatin structure rather than the primary DNA sequence. The most informative studies in this area are therefore those which look at what is going on in intact cells, and particularly useful in this respect is the chromatin immunoprecipitation (ChIP) assay. ChIP assays carried out with NIH 3T3 fibroblasts showed that E2F-4/p107 and E2F-4/p130 complexes were associated with the B-myb promoter in G0, while in early G1, only E2F-4/p107 complexes remained [37] . Free E2F-4 (i.e. devoid of pocket proteins) was detected transiently on the B-myb promoter at the G1/S transition, although no other E2F species were seen at this stage, while in S phase, no E2F or pocket proteins could be detected at all. This latter situation is unique to B-myb, since all other E2F-regulated promoters analysed bind E2F species during S phase [37] . Another study using the human T98G glioblastoma cell line also found that the B-myb promoter is uniquely free of associated E2F and pocket proteins during S phase [38] , although some details of the factors binding in G1 differed between this cell line and NIH 3T3 cells. The major discrepancy is that E2F-1 and E2F-3, but not E2F-4, were found to be associated with the B-myb promoter in T98G cells in late G1. Although the predominant E2F complexes binding to the B-myb promoter are associated with pocket proteins and are likely to repress transcription, free E2F species were detected transiently in late G1, implying that they may have a role in transactivating the promoter. This notion is consistent with studies carried out in E2F3 -/-MEFs, where the expression of B-myb and other cell cycle regulated genes such as cdc2, cyclin A2 and cdc6 is strongly impaired when quiescent cells are stimulated to reenter the cell cycle by addition of serum. In contrast, none of these genes was found to be deregulated in E2F1 -/-MEFs [39] . This study suggests that E2F-3 has a transient role in transactivating the B-myb promoter late in G1, at least in certain cell types. In opposition to this notion, a B-myb promoter containing a mutated E2F site was found to be highly active in stably transfected NIH 3T3 cells [40] . Altogether, this may point to E2F-3 activation operating through an alternative binding site in B-myb, potentially a site which is not present in the promoter sequences used in transfection experiments, and the resolution of this issue requires further study. B-myb is a highly repressed gene in quiescent cells, and recent studies have begun to address how this is achieved. Core histones on the B-myb promoter are under-acetylated in G0/early G1 when transcription is silenced, while B-myb derepression correlates with an increase in H3 and H4 acetylation [38] . These findings suggest that p107 and p130 may recruit histones deactetylases (HDACs) to the B-myb promoter at G0/early G1 and that histone acetylases (HATs) may replace HDACs during the G1/S transition ( fig. 2) . Indeed, ChIP analysis carried out on fibroblasts detected the presence of HDAC1 and the co-repressor mSin3B on the B-myb promoter during G0 [40] . Notably, the recruitment of HDAC1 and mSin3B was not observed in p107 -/-;p130 -/-MEFs and was completely abolished in a B-myb transgene harbouring a mutated E2F site. Therefore, E2F4 complexes containing p107/ p130 may repress B-myb transcription by either recruiting HDACs and co-repressors or by physically excluding HATs from the promoter at G0/early G1 ( fig. 2 ). As noted above, regulation of B-myb transcription by E2F has some unconventional features, most notably the prevalence of repressor complexes and the complete absence of associated E2F species during S phase. This eccentricity suggests unique features of the B-myb E2F site, or its context. Consistent with this notion, we encountered a co-repressor site ( fig. 2 ) referred to as the downstream repression site (DRS), which is located just a few nucleotides 3¢ of the E2F site [33] . Mutation of the DRS resulted in B-myb promoter derepression in G0 in a similar manner to mutations in the adjacent E2F site. Curiously, mutating the DRS had no effect on E2F binding in in vitro assays such as EMSA [33] . Recently, however, ChIP assays carried out on a B-myb transgene harbouring mutations in the DRS have shown that p130 and p107 binding to the E2F site is compromised in vivo [35] . We conclude that the DRS acts specifically in vivo to recruit repressor E2F-4/p107 and E2F-4/p130 complexes to the adjacent E2F site, potentially by modifying the nucleosome conformation or positioning in this region ( fig. 2 ). The presence of the DRS may therefore explain why repressor E2F complexes predominate on the B-myb promoter. Virtually all studies on B-myb transcriptional regulation have been done with cells arrested in, and released from, G0, and there is relatively little information on what happens when cells receive an inhibitory stimulus and arrest at a cell cycle checkpoint. G1 arrest triggered by p16
INK4a , transforming growth factor-b (TGF-b) and contact inhibition is mediated by E2F-dependent transcriptional repression [41] , and TGF-b-induced G1 arrest has been suggested to result from its inhibitory effect on expres-sion of B-myb and cyclin A [42] . A recent report by Chen and collegues has elucidated the cascade of events that links the activation of the TGF-b receptor with c-myc transcriptional repression [43] . Thus, TGF-b receptor activation induces phosphorylation of the Smad3 protein, some of which exists as a cytosolic complex with E2F3/4-DP1 and p107. Phosphorylated Smad3 is able to recruit Smad4 and translocate the multicomplex to the cell nucleus, where it represses TGF-b-responsive genes like c-myc. Clearly, it is of interest to determine whether a similar mechanism acts on B-myb transcription.
Cell cycle-regulated phosphorylation of B-Myb
Reflecting the strict transcriptional regulation of the Bmyb gene during the cell cycle, B-Myb protein levels are low in G0-arrested cells, but are induced in late G1 following serum stimulation and peak at the onset of S phase [44] . Interestingly, induction of expression in late G1/S is accompanied by the appearance of a more slowly migrating B-Myb form that runs at an apparent molecular weight of 112 kDa. Treatment of cell extracts with phosphatases reduced the apparent molecular weight of BMyb to 110 kDa [12, 44] , similar to that seen in G0/early G1. These reports were the first to show that B-Myb was modified by phosphorylation during S phase. The timing of this modification correlated with cyclin E and cyclin A-cdk2 activation [45] , and these cyclin/cdk complexes are the most likely candidates to phosphorylate B-Myb. Indeed, using baculovirus-expressed proteins, B-Myb was shown to be preferentially a substrate for cyclin A/cdk2 activity [44] , while cyclin E/cdk2 and cyclin D1/cdk4 had little effect. Moreover, cyclin A was able to induce a B-Myb mobility shift in transfected COS-7 and U-2 OS cells [12, 46] , while both cyclin A and cyclin E were able to do so in Saos 2 cells [47] . Importantly, cotransfection of cyclin A/cdk2 with B-Myb was found to result in a substantial enhancement of transactivation function [8, 11, 12, 47] , suggesting that the transcriptional properties of B-Myb are positively regulated by cyclin/cdk-mediated phosphorylation at late G1/S phase. Further evidence that cyclin A/cdk2 is primarily responsible for B-Myb phosphorylation in S phase has come from two-dimensional tryptic peptide mapping. This showed that cyclin A/cdk2 phosphorylated similar BMyb sites both in vitro and in vivo; furthermore, the spot pattern was very similar to that obtained from S phasesynchronised Swiss 3T3 fibroblasts [12] . The use of this methodology in combination with point mutagenesis of putative cdk phosphorylation sites (Ser/Thr-Pro) allowed the indentification of Thr443/447/490/497/524 and Ser581 as in vitro and in vivo cyclin A/cdk2 substrates [46, 48, 49] . Notably, B-Myb transcriptional activity was reduced between 40 -50 % with respect to wild type BMyb in the single point mutants T447A, T524A and S581A, while a mutant harbouring four mutated sites (T447A, T490A, T497A and S581A) was barely activated by ectopic cyclin A [46, 48] . Thus, the co-ordinated phosphorylations of different Thr and Ser residues in the B-Myb C terminus synergise to increase B-Myb transcriptional activity. More recently, the use of automated phosphopeptide radiosequencing has allowed the identificaction of several more cyclin E/A-cdk2 phosphorylation sites in B-Myb ( fig. 1) , and a mutant carrying substitutions in all 15 reported B-Myb phosphorylation sites is unable to transactivate the FGF4 promoter and behaves as a dominant negative, presumably by competing with wild-type B-Myb for binding to MBSs [50, 51] . The B-Myb C-terminus ( fig. 1 ) contains an NRD, and its deletion generates proteins with high transcriptional activity that cannot be further activated by phosphorylation [8, 11, 12, 52] . The role of phosphorylation has therefore been postulated to overcome negative regulation conferred by the NRD, and a number of studies have investigated how this mechanism may operate at the protein interaction level. One possible mechanism was suggested by the observation that one of the phosphorylation sites (S581) lies within a nuclear localisation domain. However, mutation of this site had no effect on intracellular localisation of B-Myb; moreover, the B-Myb protein remains in the cell nucleus throughout the cell cycle suggesting that phosphorylation has no effect on this property [44] . A further mechanism was suggested by the observation that C-terminally truncated B-Myb has an increased affinity for DNA [52] . However, binding of fulllength B-Myb to either a single or a concatenated MBS was not increased upon cyclin A-mediated phosporylation. Currently, the most favoured models for B-Myb activation by phosphorylation are either that this increases the affinity of B-Myb for a co-activating protein or, alternatively, reduces its affinity for a repressor protein.
B-Myb co-activators
In common with other Myb proteins, B-Myb has been found to interact both functionally and physically with the transcriptional co-activators, CREB-binding protein (CBP) and the related p300 protein [51 -53] . Both these co-activators respond to multiple signalling events by acting as scaffolding proteins that connect sequence-specific transcription factors to the basal transcriptional machinery. Additionally, p300 and CBP have intrinsic HAT activity, and therefore may be involved in chromatin remodelling through acetylation of nucleosomal histones as well as by modifying interacting transcription factors such as B-Myb [reviewed in ref. 54] . The ability of CBP to synergise with B-Myb transcriptional activity was CMLS, Cell. Mol. Life Sci. Vol. 60, 2003 Review Article found to be strictly dependent on cyclin A-mediated phosphorylation of B-Myb [52] . Surprisingly, in view of this finding, evidence obtained to date indicates that the phosphorylation status of B-Myb does not affect binding to either CBP or p300 [51, 52] . Explaining these somewhat discordant findings is uncertain at present, but a simple model in which CBP/p300 activates the transactivation function of B-Myb by specifically recognising phosphorylated domains is clearly a non-starter. Pertinent is that CBP/p300 acetylates five lysine residues in the NRD of the mouse c-Myb protein and their substitution to arginine strongly impairs c-Myb transcriptional activity [55, 56] . Since four of these lysine residues are conserved in B-Myb, one may reasonably argue that lysine acetylation is an important post-translational modification with huge implications for Myb function. One possible explanation of the results, therefore, is that cyclin Amediated phosphorylation of key serine and threonine residues located in the CR/NRD domain of B-Myb may alter the conformation of this region and allow the associated CBP/p300 access to the substrate lysines. The subsequent acetylation of these residues would account for the synergy between cyclin A and CBP/p300, and would explain why inhibiting phosphorylation ablates enhancement of B-Myb transcriptional activity. Further work in this area is required to resolve these issues. The poly(ADP-ribose) polymerase (PARP) protein has also been reported to be a co-activator of B-Myb [57] . This activity is dependent upon a physical interaction between these proteins which involves the B-Myb DNAbinding domain, but is not dependent upon the poly-ADP ribosylation activity of PARP. Notably, PARP and cyclin A synergise to drive B-Myb transcriptional activity [58] , while a B-Myb mutant containing substitutions in ten cyclin A/cdk2 phosphorylation sites [50] failed to be co-activated by PARP expression. Although these data initially suggested that PARP interacts specifically with phosphorylated B-Myb, further evidence indicated that in fact PARP facilitates phosphorylation of B-Myb. Indeed, cyclin A was found to be unable to enhance B-Myb activity in PARP -/-fibroblasts, suggesting that PARP might induce a conformational change in B-Myb that would expose C-terminal phosphorylation sites to cyclin A/cdk2 [58] . These data suggest that synergy between B-Myb and CBP/p300 could also be accounted for by a similar mechanism, as indeed we have previously proposed [52] . The interactions made by B-Myb with co-activators are summarized in figure 3 . 
B-Myb repressors
The transcriptional activity of B-Myb is repressed through interactions with the co-repressor proteins NCoR/SMRT [53, 59] and BS69 [59] . The closely related N-CoR and SMRT proteins are components of multiprotein complexes containing HDACs, which bind and repress many other transcription factors [60] . The B-Myb C terminus has recently been shown to interact with the nuclear receptor-binding domain of N-CoR, and transcriptional repression of B-Myb can be overcome by co-expressing the unliganded thyroid hormone nuclear receptor. Repression of B-Myb activity can also be overcome with the HDAC inhibitor trichostatin A (TSA), which suggests that recruitment of HDACs to an N-CoR/B-Myb or SMRT/B-Myb complex may account for the inhibitory effect. Significantly, the association with N-CoR was reduced when B-Myb was modified by cyclin A/cdk2 [53] . Furthermore, N-CoR is unable to bind to transcriptionally activated mutants of B-Myb which lack the NRD. These findings suggest a model in which N-CoR/SMRT binding to B-Myb is disrupted by cyclin A/cdk2 phosphorylation ( fig. 3 ). This would enable the acetylase activity provided by B-Myb-associated CBP/p300, now unfettered by HDAC activity associated with N-CoR/SMRT, to modify histones and other regulatory proteins (possibly including B-Myb itself) and stimulate transcription. Cterminally truncated B-Myb lacking the NRD would not require phosphorylation for this activity, as it does not bind N-CoR/SMRT. Although this is an interesting model, further work is required to prove its validity. Indeed, other researchers find that C-terminally truncated B-Myb binds N-CoR as efficiently as wild-type B-Myb [59] , and suggest that physical interactions with the BS69 protein, which was first identified as a protein that binds and inhibits the adenovirus 5 E1A oncogene [61] , contributes to the transcriptional repression activity of B-Myb.
Role of ubiquitination in regulating B-Myb activity
Another means to control protein activity is at the level of protein stability, and many regulators of the cell cycle and transcription are in fact short-lived proteins regulated by protein degradation through the ubiquitin-proteasome pathway [62, 63] . B-Myb protein levels were initially observed to be substantially reduced when cyclin A was coexpressed [46] , suggesting that phosphorylated B-Myb may be targeted for ubiquitination. Indeed, the B-Myb protein half-life was found to be reduced from 2.7 h to 50 min after cyclin A expression, while this effect was compromised by proteasome inhibitors such as lactacystin [64] . Moreover, poly-ubiquitination of wild-type B-Myb was increased in cyclin A-co-transfected cells while it barely affected the half-life of a C-terminally truncated protein, namely B-Myb . Degradation of B-Myb was accelerated in cells co-transfected with the F-box protein p45 Skp2 , which is a cell cycle-regulated component of the ubiquitin/proteasome pathway maximally expressed during S phase [64] . Ubiquitination of cyclin A/cdk2-modified B-Myb may therefore have a role in limiting the transcriptionally hyperactivated protein to S phase. More speculatively, proteasomal targeting of phosphorylated B-Myb may generate transcriptionally activated fragments from which the NRD has been excised. However, there is no evidence that C-terminally truncated B-Myb fragments accumulate in cells expressing cyclin A/cdk2 as would be predicted by this model [46] .
B-Myb cell cycle regulation: transcription factor activity
The most obvious requirement for B-Myb function in the cell cycle is as a regulator of gene transcription Indeed, the experimental use of inducible dominant interfering Myb proteins, consisting of the DNA-binding domain linked to a regulatable estrogen receptor/engrailed transcriptional repression module [52, 65] , suggests that the transcriptional activity of B-Myb is required for cell growth. These interfering proteins were designed to bind to MBSs present in the transcriptional regulatory sequences of target genes, blocking transcription through the action of the Engrailed repression domain. Mouse embryonal stem (ES) cells expressing an interfering Myb protein showed a defect in G1/S transition and an apparently independent reduction in cell adhesion. Although all three members of the vertebrate Myb family bind the same consensus MBS, and therefore may regulate the same gene set, the defects observed are likely due to interference with B-Myb-regulated transcription, since this is the only member of the family which is expressed in these primitive progenitor cells. Which target genes are affected by the interfering Myb mutant remains unknown. B-Myb notably binds the MBS less avidly than either cMyb or A-Myb and has less tolerance of binding site variations [66] . This suggests that B-Myb is a weaker transcriptional activator which could be supplanted by the other Myb family proteins in cells where they are co-expressed. However, studies to date indicate that B-Myb gene transactivation is not straightforward, being in some instances independent of DNA binding and, as discussed above, clearly affected by post-translational modifications and by the presence of co-repressors and co-activators. As discussed in detail below, a number of potential B-Myb target genes have now been proposed, and B-Myb has evidently evolved several strategies to regulate transcription.
CMLS, Cell. Mol. Life Sci. Vol. 60, 2003 Review Article MBS-independent promoter regulation is best exemplified by the human HSP70 gene. Expression of HSP70 peaks during S phase [67] , and it is notable that this coincides with maximal levels of B-Myb [21, 30] . Transactivation of the HSP70 promoter is abrogated by removal of the TATA box, suggesting that in this case B-Myb may regulate gene transcription through direct or indirect interactions with components of the basal transcriptional machinery [68] . Recently, B-Myb was suggested to be titrating out the transcriptional co-repressor N-CoR and releasing the nuclear hormone receptor TRb, which would then directly transactivate the HSP70 promoter [53] . A number of other promoters which lack MBSs have also been reported to be transactivated by B-Myb, for example, DNA polymerase alpha [69] , B-myb itself [70] and the fibroblast growth factor 4 (FGF4) promoter [51] . Although some caution is advisable in the interpretation of these results -in particular, evidence is lacking that these genes are bona fide in vivo targets for B-Myb -the ability of B-Myb to act as a promiscuous, albeit rather weak, transactivator must reflect some significant property of the protein. In this respect, of interest is that B-Myb acts through a GC-rich region containing several putative Sp1-binding sites for transactivation of its own promoter [70] . Indeed, Sp1 was found to synergize with B-Myb to transactivate the B-myb promoter [70] ; moreover, these proteins are able to interact in vivo. Association with Sp1 may therefore allow B-Myb to be recruited to promoters containing Sp1-binding sites ( fig. 2 ). As these binding sites are common promoter components, this mechanism would potentially allow B-Myb recruitment to numerous genes. B-Myb has been reported to transactivate a number of promoters through MBS-dependent regulation, although in general the data relate only to transient co-transfection/reporter assays. Transactivation of the c-myc protooncogene promoter by B-Myb appears to be mediated through several MBSs which are present in this sequence [71] , while transactivation of the human DNA topoisomerase IIa promoter appears to require a single MBS [72] . Although both of these genes have important roles in cell proliferation, there is as yet little evidence that the promoters of the endogenous genes are true targets for BMyb in vivo. Similarly, the human cyclin A1 promoter contains several MBSs close to the mRNA initiation site, and can be transactivated by B-Myb (and c-Myb) in transient co-transfection assays [49, 73] . Cyclin A1 is expressed in proliferating cells during spermatogenesis and is also transcribed in myeloid leukaemias; B-Myb is coexpressed in these cells, and may potentially regulate its expression; however, further evidence is still required to confirm this. Both c-Myb and B-Myb have recently been shown to be able to bind to the insulin-like growth factorbinding protein 5 (IGFBP) promoter in vitro (EMSA assays) and in vivo (ChIP assays), and can transactivate the promoter through an MBS. Notably, neuroblastoma cell growth is dependent on the supply of growth factors, which are frequently produced through an autocrine mechanism, suggesting that Myb proteins may be involved in the regulation of the insulin-like growth factor axis, and therefore may contribute to the neoplastic transformation of neuroblastoma cells [74] . Several studies suggest that B-Myb regulates genes which promote cell survival. Representational difference analysis carried out on LAN-5 neuroblastoma cells ectopically expressing B-Myb identified the apolipoprotein J/clusterin (clusterin) gene as a putative B-Myb target. The clusterin promoter has an MBS whose mutation impairs B-Myb transactivation in transient co-transfection assays; moreover, the activity of B-Myb on this promoter is enhanced by cyclin A2 [75] . The clusterin gene encodes a sulphated glycoprotein which accumulates during senescence and in cancer cells, and has been found to protect cells against tumour necrosis factor a-and oxidative stress-related apoptosis [reviewed in ref. 76 ]. Additionally, clusterin expression appears to increase resistance of neuroblastomas to chemotherapeutic drugs, and of interest is that high levels of B-Myb expression in neuroblastoma correlates with poor prognosis [77] . B-Myb overexpression may therefore contribute to tumour progression in neuroblastomas by enhancing cell survival through induction of clusterin. Ectopic expression of BMyb has also been found to reduce the dependence of murine T cells on cytokines while increasing their resistance to several apoptotic agents. This effect correlated with increased expression of the anti-apoptotic Bcl2 gene, and B-Myb and cyclin A were shown to co-operate to transactivate Bcl2 through a putative MBS found in the promoter [78] . Finally, B-Myb can transactivate the promoter of the surfactant protein A (SP-A) gene [79] , whose protein functions as part of the innate immunity of the lung. Although the mitotic index of lung epithelia is normally low, cdk2 and cyclin A increase after lung injury and may activate B-Myb to induce expression of SP-A in these cells. Interestingly, Myb proteins may also act as repressors of gene transcription, although again, this property of BMyb has been described only during over-expression in transfected cells. Thus, c-Myb and B-Myb repress transcription of the human c-erbB2 (HER2) promoter in an MBS-dependent way, potentially by binding to an MBS which overlaps with the TATA box and blocking access to TFIID [80] . HER2 is frequently amplified in breast adenocarcinomas [81] , and it would be interesting to know if Myb proteins can down-regulate HER2 promoter activity in cancer cells. Moreover, the bFGF-induced decrease in mRNA levels and transcription of the type I collagen a1 and a2 genes in bovine aortic smooth muscle cells (SMCs) is paralleled with induction of B-myb mRNA lev-2396 M. Joaquin and R. J. Watson Cell cycle regulation by B-Myb els [82, 83] , and co-transfection experiments showed that B-Myb strongly repressed transcription from the promoters of these collagen genes. The repression mechanism is not yet known, but both promoters contain putative MBSs and B-Myb may prevent c-Myb from activating transcription through this site, as has been proposed for the human type I collagen a2 promoter [84] . However, BMyb appears to bind MBSs more weakly than does cMyb and, arguably, B-Myb would be a better competitor at the protein-protein interaction level rather than as a DNA-binding competitor. Indeed, transcriptional downregulation by B-Myb of the type V collagen a2 gene in aortic SMCs occurs through a promoter region which lacks MBSs, and this has been suggested to occur via interaction with a positively acting matrix regulatory factor, termed MRF-V [85] . Taken together, these findings show the relevance of Myb proteins as key regulators of collagen gene expression.
B-Myb cell cycle regulation: interactions with regulatory proteins
B-Myb has been reported to bind to several cell cycle regulatory proteins, including cyclin D1 [86] , cyclin A1 [49] and p107 [87] , suggesting that these interactions may contribute to the role of B-Myb in cell growth. In this respect, of great interest is that a dual role as transcriptional activator and component of a DNA replication complex has been proposed for the Drosophila Myb protein [88] , which appears to be more closely related to B-Myb than to either c-Myb or A-Myb [89] . Moreover, some studies indicate that the ability of B-Myb to overcome inhibitory effects on the cell cycle does not depend upon its transcriptional activity. Thus, ectopically expressed B-Myb was found to bypass a proliferation block induced by p53/p21Cip1 in a human glioblastoma cell line [27] , and this activity could also be conferred by a transcriptionally defective B-Myb mutant. We have been unable to demonstrate binding in vivo between B-Myb and either p53 or p21Cip1 [unpublished results], and the molecular mechanism behind this observation remains to be elucidated. Moreover, we have demonstrated that the ability of BMyb to overcome a G1 cell cycle block imposed by p107, a member of the retinoblastoma pocket protein family [90] , is also independent of the transcriptional activity of B-Myb [91] . In Saos-2 cells, p107 causes G1 arrest through two mechanisms specified by distinct protein domains: the action of the large pocket domain that binds E2F and an extensive N-terminal domain that binds and inhibits cyclin/cdk2 complexes [92, 93] . We found that BMyb binds to the p107 N terminus (between amino acids 10 -486) in a domain that overlaps a cyclin A/E-binding motif [91] , suggesting that the critical function that BMyb bypasses is inhibition of cyclin/cdk2 activity. In support of this notion, we could demonstrate that p107-mediated inhibition of cyclin E/cdk2 is overcome by B-Myb expression in co-transfected Saos-2 cells. Significantly, the B-myb and p107 genes are both under E2F transcriptional control, and their expression is co-ordinately induced in late G1. One function of B-Myb therefore may be to counteract inhibition of cyclin/cdk2 activity by de novo synthesised p107 at the critical G1/S boundary ( fig.  3) . The requirement for this interaction may be cell type dependent and, of course, would be influenced by the relative abundance of B-Myb and p107. B-Myb is highly expressed in ES cells, whose growth appears to depend critically upon B-Myb [24] , and the majority of p107 in these cells can be depleted by immunoprecipitating with a B-Myb antibody [unpublished results].
The domains of B-Myb required for p107 binding are quite ill-defined -deletions within the extreme C-terminal NRD as well as the acidic region both ablate binding [91] -suggesting that the interaction interface is conformational rather than linear. The involvement of the NRD raises the possibility that p107 binding may repress BMyb transcriptional activity through this domain. Clearly, however, B-Myb also makes interactions with other proteins through C-terminal sequences, including N-CoR, and function of the NRD is unlikely to be ascribable to association with a unique co-repressor protein.
Interactions with cyclin D1 and cdk9 do not appear to result in phosphorylation of B-Myb, and in neither instance does binding depend upon enzymatic activity associated with these proteins [86, 94] . Rather, direct interactions with either cyclin D1 or cdk9 inhibit B-Myb transcriptional activity, indicating that these proteins are negative regulators ( fig. 3) . The association between endogenous B-Myb and cyclin D1 takes place in cells enriched at the G1/S boundary [86] . Since B-Myb function seems to be crucial during the G1/S transition, cyclin D1 may hold BMyb in a transcriptionally inactive complex in G1 until such time in late G1/S when cyclin D1 is proteolytically degraded or B-Myb is activated by cyclin A/cdk2. In support of this hypothesis, B-Myb transcriptional activity has recently been reported to be enhanced during the early stages of neural differentiation, and this coincided with reduced association with cyclin D1 [95] . In contrast to cyclin D1, cdk9 levels are not cell cycle regulated and the physiological relevance of the interaction with B-Myb is not yet obvious. The expression of the cyclin A1 gene is restricted to a very few tissues; namely, testis, haematopoietic precursors and several myeloid leukaemic cell lines [96, 97] . Cyclin A1 interacts with the B-Myb C terminus in vitro and these proteins appear to be associated in vivo in leukaemic cells. In contrast to cyclin D1 and cdk9, cyclin A1/cdk2 induces B-Myb activity by phosphorylating key threonine and serine residues [49] . Notably, despite the great similarity between cyclin A1 and cyclin A2, no associa-CMLS, Cell. Mol. Life Sci. Vol. 60, 2003 Review Article 2397 tion between B-Myb and cyclin A2 has been detected in leukaemic cells [49] , mouse embryonic stem cells or in transfection experiments [unpublished results] suggesting that the B-Myb-cyclin A1 association is highly specific. Since B-Myb is co-expressed in both male germ cells [98] and haematopoietic cells [16] , it would be interesting to know its relationship with cyclin A1 in these cells.
Perspectives
The B-myb gene is subject to two levels of control during the cell cycle: at the transcriptional level through the action of the E2F and Rb family of proteins and at the posttranslational level through the action of late G1/S phasespecific kinases, in particular cyclin A/cdk2. The first mechanism ensures that B-myb is transcribed only in proliferating cells, and directs maximal synthesis of B-Myb protein to late G1/S in cycling cells. The second mechanism ensures that the transcriptional activity of B-Myb in cycling cells, where B-Myb protein is present throughout the cell cycle (albeit at fluctuating levels), is enhanced specifically in late G1/S. The existence of these coupled regulatory modes points to the inescapable conclusion that B-Myb plays a significant role in the cell cycle during late G1/S. At present, however, we are only scratching the surface in our understanding of the precise nature of this role. Experimental evidence points to a two-fold role for BMyb in the cell cycle: (i) by acting as a transcription factor to regulate expression of genes required for cell cycling and (ii) by making direct interactions with cell cycle regulators such as p107 and p57 Kip2 . Significantly, the related Drosophila Myb protein has been shown to function both in transcriptional regulation and more directly as part of a DNA replication complex, and these studies in the fly may help us understand what B-Myb does in the mammalian cell cycle. Notable in this respect is that Drosophila Myb mutants display defects in progression through both S and M phases of the cell cycle and accumulate chromosomal abnormalities [99 -101] . Conversely, over-expressing Drosophila Myb induces cell cycle progression through S and M phases and suppresses endoreduplication [102] . Although the precise effects seen in these experiments depended on the cell type analysed, the fly protein is clearly intimately involved in the cell cycle. Effects on G2/M progression have been ascribed to the involvement of Drosophila Myb in transcription of the cyclin B gene [103] , while effects on G1/S progression may depend upon the induction of other Myb targets or may result from its direct role in DNA replication [88, 101] . In common with the Drosophila homologue, over-expression of B-myb has been shown to promote progression of certain cells into S phase [11, 104] , in particular when it is co-expressed with cyclin A. Unclear at present is whether this results from the induction of target gene transcription, direct effects upon cell cycle regulators or indeed their combination. Our experiments in Saos-2 cells indicate that the ability to interact with p107 is required for this activity, as transcriptionally hyperactive BMyb mutants which had lost the p107-binding function were unable to co-operate with cyclin A to promote S phase [unpublished results]. Overall, our experiments indicate that one of the major B-Myb functions contributing to G1/S progression is maintenance of sufficient levels of cyclin E/cdk2 and possibly cyclin A/cdk2 activity [91] . Notably, both these kinases play vital roles in progression into and progress through S phase. Gene knock-out studies have shown decisively that BMyb plays a critical role in early embryogenesis [24] . The embryonal defect is so early, however, that sufficient quantities of cells cannot be obtained from the mutant embryos to allow biochemical analyses of the defect. Conditional gene knock-outs based on the Cre/loxP system are under development, and there is now the potential to ablate B-myb expression in cell cultures using RNA interference. These developing technologies should enable rapid progress in understanding the role of B-Myb in the cell cycle.
